UroGen Pharma Ltd.

During thethree months ended* December 31, 2025,none of our directors or officers (as defined in Rule16a*-1(f) under the Exchange Act) adopted or terminated any “Rule10b5-1 trading arrangement” or “non-Rule10b5-1 trading arrangement,” as those terms are defined in Item408 of Regulation S-K.

Notice of2026* Annual Meeting Date and Related Deadlines*

As of the date of this Annual Report, we intend to hold our2026 Annual Meeting of Shareholders (the*"2026* Annual Meeting of Shareholders") on or about* June 22, 2026.This date is more than30* days before theone-year anniversary of our2025 annual meeting of shareholders, which was held on* August 26, 2025.*

Under the Israeli Companies Law,5759-1999 and the regulations promulgated thereunder (collectively, the “Companies Law”),one or more shareholders holding at least1% of the voting rights in the Company* mayrequest that our Board include a matter in the agenda of a general meeting of shareholders to be convened in the future (or5%* if the matter is the appointment or removal of a director), provided that it is appropriate to discuss such a matter at the general meeting. Our articles of association currently provide that any shareholder holding at least1% of the outstanding voting rights* may*make such a request.

In addition to the eligibility requirements under the Companies Law, our articles of association specify additional procedural requirements for shareholder proposals. Under our articles of association, in the event that the date of the annual general meeting is advanced more than30 days prior to the anniversary of the preceding year’s annual general meeting, notice by the proposing shareholder, in order to be timely, must be receivedno earlier than the close of business120 days prior to such annual general meeting,* February 22, 2026,andno* later than the close of business90 days prior to such annual general meeting,* March 24, 2026.*

In addition, shareholder proposals* maybe submitted for inclusion in a proxy statement under Rule14a*-8 under the Exchange Act. Under Rule14a-8 of the Exchange Act, to be eligible for inclusion in our proxy materials for the2026 Annual Meeting of Shareholders, shareholder proposals must be received by us a reasonable time before we begin to print and send our proxy materials. We have determined that* March 27, 2026,which is the date disclosed in our definitive proxy statement on Schedule14A* for our2025 annual meeting of shareholders, remains a reasonable time before we expect to begin to print and distribute our proxy materials for our2026 Annual Meeting, and that any shareholder proposals must be received on or before the close of business on that day. In addition, Rule14a-8 proposals must otherwise comply with the requirements of the rule. Additional requirements regarding shareholder proposals submitted for inclusion in our proxy materials for an annual general meeting of shareholders can be found in the articles of association, which is available as an exhibit to this Annual Report. Proposals should be addressed to: UroGen Pharma Ltd.,400 Alexander Park Drive,4th Floor, Princeton, New Jersey08540, Attention: Corporate Secretary.

In addition to satisfying the foregoing requirements under our articles of association, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than our board of directors’ nominees must provide notice that sets forth any additional information required by Rule14a-19 promulgated under the Exchange Act.